explore -WSS

explore

author：fashion 2025-10-01 18:34:25 - browse：816

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： The strange history of BMI, the body mass index

WSS

What causes rare myocarditis in young men after Covid vaccines?

Dems pitch expanding Medicare power to negotiate drug prices

New lawsuit accuses health insurer Cigna of denying claims in bulk

Biogen says it will cut costs by $700 million, slash 1,000 jobs

GOP inquiry over gain

Senate panel puts off hardest PBM reforms for another day

hotspot

explore

explore

Medical records are filled with copy

Here's how to stay safe from wildfire smoke amid reduced air quality

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

ADA: All diabetes patients should be screened for liver condition

State Dept. review finds Biden bears some blame for Afghanistan failures

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Moonlake's readout produced a cash windfall. Risks remain

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Medical leaders decry Supreme Court decision on affirmative action

In the gardens at Boston Children's Hospital, families find sanctuary

explore

What causes rare myocarditis in young men after Covid vaccines?

The strange history of BMI, the body mass index

UnitedHealth wins $3.3 billion takeover of Amedisys

The battle over 'scope creep' and who gets to be called 'doctor'

Supreme Court strikes down Biden student loan forgiveness program

Tuskegee Airman Raymond Cassagnol dies at 102

Wikipedia

explore

focus

explore